Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed GBM
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Afatinib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 15 Sep 2017 Status changed from active, no longer recruiting to completed.
- 08 May 2017 Planned End Date changed from 1 Apr 2017 to 29 Sep 2017.
- 08 May 2017 Planned primary completion date changed from 1 Apr 2017 to 29 Sep 2017.